A novel approach to the differential prognosis of early and late preeclampsia
https://doi.org/10.17749/2313-7347.2018.12.2.055-061
Abstract
In the present review, a new approach to studying the pathogenesis and predicting the development of preeclampsia (PE) – namely, the determination of matrix metalloproteinases (MMPs) – is discussed. Currently, the major cause of PE is thought to be an incomplete remodeling of spiral arteries because of an insufficient number of invading cytotrophoblasts or the absence/inactivation of crucial lysing enzymes, i.e. matrix metalloproteinases. The role of MMP-1, MМP-2, MМP-3, MМP-7, MМP-9 in the placenta formation, the development of oxidative stress and endothelial dysfunction is described. We propose that in the future, the MMPs may be used for differentially predicting early and late PE.
About the Authors
A. N. Strizhakov
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Strizhakov Alexander Nikolaevich – Academician of RAS, MD, Professor, Head of Department of Obstetrics and Gynecology, Faculty of General and Preventive Medicine
8, str. 2, ul. Trubetskaya, Moscow, 119991
Е. V. Timokhina
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Timokhina Elena Vladimirovna – MD, Professor, Department of Obstetrics and Gynecology, Faculty of General and Preventive Medicine
8, str. 2, ul. Trubetskaya, Moscow, 119991
S. M. Ibragimova
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Ibragimova Sapiyat Magomedalievna – Postgraduate Student, Department of Obstetrics and Gynecology, Faculty of General and Preventive Medicine
8, str. 2, ul. Trubetskaya, Moscow, 119991
V. S. Belousova
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Belousova Vera Sergeevna – Associate Professor, Department of Obstetrics, Gynecology and Perinatology, Faculty of General and Preventive Medicine
8, str. 2, ul. Trubetskaya, Moscow, 119991
Ya. O. Martirosyan
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Martirosyan Yana Ovannesovna – Medical Student
8, str. 2, ul. Trubetskaya, Moscow, 119991
References
1. Lisonkova S., Sabr Y., Mayer C. et al. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014; 124 (4): 771-81. DOI: 10.1097/AOG.0000000000000472.
2. World Health Organization – data and evidence. URL: http://www.euro.who.int/ru. [Accessed: 14.05.2018].
3. Strizhakov A.N., Timokhina E.V., Pitskhelauri E.G. et al. Pre-eclampsia today: pathogenesis and predictive and therapeutic options. [Preeklampsiya segodnya: patogenez i vozmozhnosti prognozirovaniya i lecheniya]. Voprosy ginekologii, akusherstva i perinatologii. 2016; 15 (3): 24-31 (in Russian).
4. Makatsariya A.D., Bitsadze V.O., Akinshina S.V. Severe forms of pre-eclampsia as a manifestation of thrombotic microangiopathy. [Tyazhelye formy preehklampsii kak proyavlenie tromboticheskoj mikroangiopatii]. Akusherstvo i ginekologiya. 2017; 4: 21-6 (in Russian).
5. Khodzhaeva Z.S., Kogan E.A., Klimenchenko N.I. et al. Clinical and pathogenetic features of early and late preeclampsia. [Kliniko-patogeneticheskie osobennosti rannej i pozdnej preehklampsii]. Akusherstvo i ginekologiya. 2015; 1: 12-7 (in Russian).
6. Mikhaleva L.M., Gracheva N.A., Biryukov A.E. Clinical and anatomical aspects of preeclampsia: modern features of the current. [Kliniko-anatomicheskie aspekty preehklampsii: sovremennye osobennosti techeniya]. Arhiv patologii. 2018; 80 (2): 11-7 (in Russian).
7. Maged A.M., Aid G., Bassiouny N. et al. Association of biochemical markers with the severity of pre-eclampsia. Int J Gynaecol Obstet. 2017; 136 (2): 138-44.
8. Dubovoy A.A. Severe preeclampsia: features of angiogenic status. [Tyazhelaya preehklampsiya: osobennosti angiogennogo statusa]. Avtoref dis. kand. med. nauk. Volgograd. 2016: 22 s (in Russian).
9. Espino Y., Sosa S., Flores-Pliego A. et al. New Insights into the Role of Matrix Metalloproteinases in Preeclampsia. Int J Mol Sci. 2017; 18 (7): pii: E1448. DOI: 10.3390/ijms18071448.
10. Rasstrigina I.M., Milovanov A.P., Fokina T.V., Kadyrov M. Intensity of expression of metalloproteinases of the 2nd and 9th types by invasive trophoblast cells in uncomplicated pregnancy and preeclampsia. [Intensivnost' ekspressii metalloproteinaz 2-go i 9-go tipov kletkami invazivnogo trofoblasta pri neoslozhnennoj beremennosti i preehklampsii]. Arhiv patologii. 2014; 3: 24-9 (in Russian).
11. Whitley G.S.J., Cartwright J.E. Cellular and molecular regulation of spiral artery remodelling: lessons from the cardiovascular field. Placenta. 2010; 31 (6): 465-74.
12. Anacker J., Segerer S.E., Hagemann C. et al. Human decidua and invasive trophoblasts are rich sources of nearly all human matrix metalloproteinases. Mol Hum Reprod. 2011; 17 (10): 637-52.
13. Rahat B., Sharma R., Bagga R. et al. Imbalance between matrix metalloproteinases and their tissue inhibitors in preeclampsia and gestational trophoblastic diseases. Reproduction. 2016; 152 (1): 11-22.
14. Bonnans C., Chou J., Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014; 1
15. (12): 786-801. 15. Vetrov V.V., Voinov V.A., Ivanov D.O. Uncomplicated preeclampsia. [Neoslozhnennaya preehklampsiya]. SPb.: Inform-Navigator. 2012: 168 s (in Russian).
16. Plaks V., Rinkenberger J., Dai J. et al. Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Proc Natl Acad Sci USA. 2013; 110 (27): 11109-14.
17. Su P., Tsai H., Tsai Y. et al. miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9. Biofactors. 2017; 43 (2): 210-9.
18. Reister F., Kingdom C.J., Ruck P. et al. Altered protease expression by periarterial trophoblast cells in severe early-onset preeclampsia with IUGR. J Perinat Med. 2006; 34 (4): 272-9.
19. Nugent W.H., Mishra N., Strauss J.F., Walsh S.W. Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via ProteaseActivated Receptor 1. Reprod Sci. 2016; 23 (4): 542-8.
20. Miroshina E.D., Tyutyunnik N.V., Khramchenko N.V. et al. Modern diagnostic methods of preeclampsia (a review). [Diagnostika preeklampsi in a sovremennom etape (obzor literatury)]. Problemy reproduktsii. 2017; 23 (1): 96-101.
21. Palei A.C., Sandrim V.C., Duarte G. et al. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta. 2010; 411 (11-12): 874-7.
22. Palei A.C., Granger J.P., Tanus-Santos J.E. Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets. 2013;14 (3): 325-34.
23. Feng H., Wang, L., Zhang M. et al. Ratio of matrix metalloproteinase-2 to -9 is a more accurate predictive biomarker in women with suspected preeclampsia. Biosci Rep. 2017; 37 (2): pii: BSR20160508. DOI: 10.1042/BSR20160508.
24. Martinez-Fierro M.L., Perez-Favila A., Garza-Veloz I. et al. Matrix metalloproteinase multiplex screening identifies increased MMP-2 urine concentrations in women predicted to develop preeclampsia. Biomarkers. 2018; 23 (1): 18-24.
25. Erez O., Romero R., Maymon E. et al. The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One. 2017; 12 (7): e0181468. DOI: 10.1371/journal.pone.0181468.
Review
For citations:
Strizhakov A.N., Timokhina Е.V., Ibragimova S.M., Belousova V.S., Martirosyan Y.O. A novel approach to the differential prognosis of early and late preeclampsia. Obstetrics, Gynecology and Reproduction. 2018;12(2):55-61. (In Russ.) https://doi.org/10.17749/2313-7347.2018.12.2.055-061
Views: 924
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
